Moteur de recherche d’entreprises européennes
Financement de l’UE (2 999 975 €) : Déchaîner les outils diagnostiques et thérapeutiques pour la syphilis pendant la grossesse, la neurosyphilis et l’échec du traitement. Hor28/07/2025 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Déchaîner les outils diagnostiques et thérapeutiques pour la syphilis pendant la grossesse, la neurosyphilis et l’échec du traitement.
For over 50 years, the tools for diagnosing, preventing, and treating syphilis have seen minimal progress, partly due to limitations in bacterial cultivation. Existing tools were primarily drawn from research on early-stage syphilis and evidence extrapolated to severe forms of the infection, leaving important unmet needs like the lack of predictive markers for neurosyphilis and mother-to-child-transmission, limited evidence on treatments for these conditions, and challenges in monitoring treatment failure. This project aims to shift the paradigm by demonstrating that the diverse manifestations of syphilis are not merely random infections in different bodily compartments but are intricately linked to unique bacterial traits and host responses that necessitate specific tools. Our goal is to discover manifestation-specific biomarkers, repurpose antibiotics for tailored treatments, and pioneering TPA isolation methods for treatment monitoring. Taking advantage of a unique network of collaborators in areas with a high incidence of severe syphilis, I will examine how severe clinical manifestations relate to genomic variations in TPA strains and with host humoral responses. A groundbreaking pan-proteomic array will allow identifying markers linked to clinical phenotypes and it will open avenues for discovery of new antigens as vaccine candidates. Furthermore, I will exploit the established expertise of my team on drug repurposing and conducting randomized clinical trials to evaluate the efficacy of alternative antibiotics to cure patients with neurosyphilis and syphilis in pregnancy. Finally, I aim to pioneer methods for the first-time isolation of TPA from patient samples and conduct antimicrobial resistance testing in treatment failures. The resulting tools will be a tremendous resource for preventing adverse outcomes like neurological sequelae, stillbirth, congenital syphilis and treatment failure, especially in low-middle-income countries where most complications occur
https://cordis.europa.eu/project/id/101171779
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
